Filing identity and reporting period
Important identity mismatch: The supplied filing is ZIOPHARM Oncology, Inc.’s Form 10-K for the fiscal year ended December 31, 2011, not a filing by Alaunos Therapeutics, Inc. It reports full-year results, not a standalone fourth quarter. The company described itself as a development-stage biopharmaceutical business focused on oncology.
Financial results and liquidity
| Metric | 2011 | 2010 |
|---|---|---|
| Revenue | $0.667 million | None |
| Research and development expense | $57.1 million | $12.9 million |
| General and administrative expense | $15.0 million | $11.6 million |
| Net loss | $63.8 million | $32.7 million |
| Basic and diluted loss per share | $0.97 | $0.71 |
| Cash and cash equivalents at year-end | $104.7 million | $60.4 million |
| Net cash used in operating activities | $38.8 million | $19.7 million |
| Working capital | $92.7 million | $57.2 million |
Revenue was collaboration funding from Solasia, not product sales. Product candidates had not received marketing approval. Operating loss was $71.4 million; the reported net loss was reduced by a $7.6 million non-cash gain from remeasurement of warrant liabilities. The filing does not present meaningful product gross margins. No borrowing debt is identified; total liabilities were $36.5 million, including $19.4 million of warrant liabilities.
Total assets were $108.1 million and stockholders’ equity was $71.6 million at year-end. The company reported $187.6 million of cumulative losses since inception. In January 2012, it raised approximately $49.1 million net from a public stock offering; including that financing, management estimated cash would fund operations into the second half of 2013. This estimate was subject to substantial uncertainty and the company had no other committed capital source.
Material changes versus the prior comparable period
- Net loss increased by $31.1 million year over year, while R&D expense rose $44.2 million (342%). Drivers included a $17.5 million non-cash Intrexon-related in-process R&D charge, higher clinical-trial and manufacturing costs, and increased staffing.
- Operating cash use increased $19.1 million to $38.8 million, largely reflecting expanded development activity.
- Cash increased by $44.3 million during 2011, principally due to $84.3 million of financing cash inflows, including public and private equity financing and warrant exercises.
- Revenue of $0.7 million began in 2011 from the Solasia collaboration; the $5.0 million upfront research-funding payment is recognized over an estimated 75-month performance period.
Programs, outlook, and principal risks
- Palifosfamide: The pivotal PICASSO 3 Phase 3 trial in front-line metastatic soft-tissue sarcoma targeted 424 patients. Enrollment had started more slowly than anticipated; management expected completion by the end of Q1 2012 and anticipated progression-free-survival results late in the second half of 2012, subject to enrollment and other uncertainties. The independent monitoring committee had recommended continuation at its three reviews. A Phase 1 combination study for small-cell lung cancer was completed, with a potentially pivotal trial expected to begin in the second half of 2012.
- Post-year-end clinical update: In February 2012, the company reported preliminary overall-survival results from the randomized Phase 2 PICASSO study: ITT hazard ratio 0.79 and modified ITT hazard ratio 0.78, with more than 70% of events reported. These were preliminary company-reported results, not the outcome of PICASSO 3.
- Intrexon programs: ZIN-CTI-001 and ZIN-ATI-001 were in Phase 1 studies. In the small ZIN-CTI-001 melanoma study, disease control was reported in 50% of eight evaluable patients; one severe adverse event involving diarrhea, hypotension, and reversible acute renal failure was reported. The collaboration provides Intrexon 50% of net profits on product sales and 50% of sublicense revenue, subject to agreement terms.
- Other candidates: Indibulin and oral darinaparsin remained in early clinical development. Solasia received exclusive rights to develop and commercialize darinaparsin in specified Asia-Pacific territories; potential payments included up to $32.5 million in development milestones and $53.5 million in sales milestones, plus royalties. These amounts are contingent, not assured.
- Spending outlook: For the next 12 months, management forecast approximately $94.1 million of R&D expense and $19.0 million of G&A expense. It expected continued losses and anticipated needing additional financing for longer-term development.
- Key risks: Clinical failure or delay, especially PICASSO 3 enrollment and results; limited cash runway and possible dilutive fundraising; dependence on external manufacturers, CROs, licensors, and Intrexon; regulatory and commercialization uncertainty; competition; and potential limits on use of tax-loss carryforwards. Contractual obligations totaled $18.2 million, including $11.0 million of contract milestone payments, largely dependent on clinical and enrollment events.
- Controls and audit: Management and the auditor reported effective internal control over financial reporting as of December 31, 2011. The auditor issued an unqualified opinion on the financial statements.
Important facts for investors to verify
- Confirm that ZIOPHARM’s 2011 10-K is the intended filing; the request names Alaunos Therapeutics and specifies 2011 Q4.
- Review audited statements and notes for the composition, valuation assumptions, and potential dilution from the $19.4 million warrant liability and outstanding warrants.
- Check subsequent PICASSO 3 enrollment, endpoint results, regulatory interactions, and whether reported Phase 2 survival findings are confirmed in the pivotal trial.
- Assess cash use against the stated second-half-2013 runway, the January 2012 offering proceeds, and the forecast R&D and G&A spending.
- Verify the terms, funding recognition, milestone conditions, and continuing obligations under the Intrexon and Solasia agreements.